Sanofi Secures Key Regulatory Wins for Dupixent and Sleeping Sickness Treatment
Summary
Sanofi announced multiple positive regulatory updates, including a new FDA approval for Dupixent in allergic fungal rhinosinusitis and positive EU recommendations for Dupixent in pediatric chronic spontaneous urticaria and for Acoziborole Winthrop in sleeping sickness.
Key Events
-
Dupixent Receives FDA Approval for Allergic Fungal Rhinosinusitis (AFRS)
Sanofi and Regeneron's Dupixent has been approved by the US FDA as the first and only medicine for adults and children aged 6 years and older with AFRS who have a history of sino-nasal surgery. This expands Dupixent's indications to nine distinct diseases driven by type 2 inflammation.
-
Acoziborole Winthrop Gets CHMP Positive Opinion for Sleeping Sickness
Acoziborole Winthrop, co-developed by DNDi and Sanofi, received a positive opinion from the European Medicines Agency's CHMP as a single-dose oral treatment for both early and advanced-stage gambiense sleeping sickness. Sanofi will donate the medicine to the WHO.
-
Dupixent Recommended for EU Approval in Pediatric Chronic Spontaneous Urticaria (CSU)
The CHMP adopted a positive opinion recommending EU approval for Dupixent to treat moderate-to-severe CSU in children aged two to 11 years with inadequate response to antihistamines. A final decision is expected in the coming months.
Analysis
This filing highlights multiple positive regulatory developments for Sanofi, significantly bolstering its product pipeline and market reach. The FDA approval for Dupixent in allergic fungal rhinosinusitis (AFRS) expands the market for a key growth driver, establishing it as the first and only approved medicine for this condition. Additionally, the positive CHMP opinions for Dupixent in pediatric chronic spontaneous urticaria (CSU) and for Acoziborole Winthrop in sleeping sickness further demonstrate Sanofi's ongoing success in advancing its portfolio. The Acoziborole recommendation, while primarily humanitarian with Sanofi donating the medicine, underscores the company's commitment to global health. These positive updates come as Sanofi's stock is trading near its 52-week low, potentially offering a catalyst for investor sentiment.
At the time of this filing, SNY was trading at $46.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.3B. The 52-week trading range was $44.62 to $60.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.